INVESTOR PRESENTATION NOVEMBER 2021 ♡ BEAUTYHEALTH® This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company"), the calculation of certain key financial and operating metrics, capital expenditures, the introduction of new products, expansion into new markets and the ability to execute certain strategic initiatives. Some of the forward-look ...

[PART I—FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%E2%80%94FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) The company's Q3 2021 financial statements reflect **significant** post-**Business Combination** **changes**, **impacting** assets, liabilities, and profitability [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The **balance sheet** as of September 30, 2021, shows **significant** asset and liability **growth**, **driven by** cash and **convertible notes** Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2021 | Dec 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $718,622 | $9,486 | | Total current assets | $797,805 | $59,095 | | Goodwill | $122,865 | $98,531 | | Total assets | $997,875 | $222,835 | | **Liabilities & Equity** | | | | Total current liabilities | $49,468 | $30,930 | | Warrant liabilities | $357,173 | $— | | Convertible senior notes, net | $728,858 | $— | | Total liabilities | $1,139,930 | $252,795 | | Total stockholders' deficit | $(142,055) | $(29,960) | [Condensed Consolidated Statements of Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) Q3 2021 **net sales** **grew** **97.2%**, but a **significant net loss** was **driven by** non-cash **warrant liability** charges Q3 2021 vs Q3 2020 Performance (in thousands, except per share data) | Metric | Q3 2021 | Q3 2020 | | :--- | :--- | :--- | | Net sales | $68,147 | $34,560 | | Gross profit | $46,075 | $20,957 | | Loss from operations | $(5,456) | $2,785 (Income) | | Change in fair value of Warrant liabilities | $199,306 | $— | | Net loss | $(215,145) | $(2,214) | | Net loss per share | $(1.63) | $(0.06) | Nine Months 2021 vs 2020 Performance (in thousands, except per share data) | Metric | Nine Months 2021 | Nine Months 2020 | | :--- | :--- | :--- | | Net sales | $182,197 | $81,212 | | Gross profit | $125,066 | $44,162 | | Loss from operations | $(29,427) | $(12,471) | | Change in fair value of Warrant liabilities | $271,333 | $— | | Net loss | $(357,797) | $(21,682) | | Net loss per share | $(4.10) | $(0.64) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Nine-month **cash flow** shows **significant financing inflows** offsetting **operating** and **investing outflows** Nine Months Ended Sep 30, 2021 Cash Flow Summary (in thousands) | Category | 2021 | 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | $(31,640) | $(12,025) | | Net cash used in investing activities | $(29,201) | $(2,697) | | Net cash from financing activities | $770,825 | $19,193 | | **Net increase in cash** | **$709,984** | **$4,471** | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the **reverse recapitalization**, **distributor acquisitions**, **convertible note issuance**, and **warrant redemption** - The **Business Combination** was accounted for as a **reverse recapitalization**, with **HydraFacial** as the **accounting acquirer** and **Vesper Healthcare** as the acquired company[29](index=29&type=chunk)[32](index=32&type=chunk) - In June and July 2021, the company acquired four of its product **distributors** in Australia, France, Germany, and Mexico to **directly sell into those markets**[60](index=60&type=chunk) Disaggregated Revenue (in thousands) | Product Line | Nine Months Ended Sep 30, 2021 | Nine Months Ended Sep 30, 2020 | | :--- | :--- | :--- | | Delivery Systems | $96,798 | $35,981 | | Consumables | $85,399 | $45,231 | | **Total net sales** | **$182,197** | **$81,212** | - On September 14, 2021, the company issued **$750 million** in **1.25% Convertible Senior Notes** due 2026 The initial conversion price is approximately **$31.76** per share[83](index=83&type=chunk)[85](index=85&type=chunk) - Subsequent to quarter-end, the company completed a **redemption of its public warrants**, resulting in **cash proceeds** of **$185.4 million** from exercises[147](index=147&type=chunk)[148](index=148&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=30&type=section&id=Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses **strong revenue rebound**, **improved gross margin**, **increased operating expenses**, and **enhanced liquidity** post-COVID [Results of Operations](index=35&type=section&id=Results%20of%20Operations) Q3 2021 **net sales** **increased** **97.2%**, **gross margin improved**, but **operating expenses surged**, leading to an **operating loss** Q3 2021 vs Q3 2020 Net Sales (in millions) | Category | Q3 2021 | Q3 2020 | Change (%) | | :--- | :--- | :--- | :--- | | Delivery Systems | $36.2 | $15.9 | +127.2% | | Consumables | $32.0 | $18.6 | +71.5% | | **Total net sales** | **$68.1** | **$34.6** | **+97.2%** | - **Gross margin improved** to **67.6%** in Q3 2021 from **60.6%** in Q3 2020, **attributed to** fixed cost leverage from **higher sales**, **improved** average selling prices, and cost savings initiatives[190](index=190&type=chunk) - **Selling and marketing expenses increased 188.9%** YoY in Q3, **driven by higher sales** commissions (**$5.2M**), **personnel-related expenses** (**$6.8M**), training (**$1.4M**), and marketing spend (**$1.4M**) as markets reopened[191](index=191&type=chunk) - **General and administrative expenses rose 172.2%** YoY in Q3, **primarily due to increased stock-based compensation** (**$3.9M**), **personnel costs** (**$1.3M**), **public company costs** (**$1.7M**), **legal fees** (**$1.2M**), and **transaction costs** (**$0.9M**)[194](index=194&type=chunk) [Liquidity and Capital Resources](index=39&type=section&id=Liquidity%20and%20Capital%20Resources) **Liquidity significantly enhanced** by **$718.6 million** cash, **primarily** from the **Business Combination** and **convertible notes issuance** - As of September 30, 2021, the company had cash and cash equivalents of approximately **$718.6 million**[205](index=205&type=chunk) - **Primary sources of funding** have been **cash flow** from **operations**, the **Business Combination**, and the **issuance** of **$750 million** in **convertible notes** in September 2021[205](index=205&type=chunk) - Subsequent to the quarter, the company received **$185.4 million** in **cash proceeds** from the exercise of **public warrants** in connection with a redemption notice issued on October 4, 2021[208](index=208&type=chunk) [Non-GAAP Financial Measures](index=44&type=section&id=Non-GAAP%20Financial%20Measures) Management uses **non-GAAP measures** like **Adjusted EBITDA** and **Adjusted Gross Profit** to assess **operating performance** Reconciliation of Net Loss to Adjusted EBITDA (in thousands) | Line Item | Q3 2021 | Q3 2020 | | :--- | :--- | :--- | | Net loss | $(215,145) | $(2,214) | | Adjustments (e.g., change in warrant FV, D&A, SBC, interest, taxes) | $220,945 | $9,769 | | **Adjusted EBITDA** | **$5,800** | **$7,555** | | **Adjusted EBITDA margin** | **8.5%** | **21.9%** | Reconciliation of Gross Profit to Adjusted Gross Profit (in millions) | Line Item | Q3 2021 | Q3 2020 | | :--- | :--- | :--- | | Gross profit | $46.1 | $21.0 | | Stock-based compensation | $0.1 | $— | | Depreciation & amortization | $2.6 | $2.7 | | **Adjusted gross profit** | **$48.7** | **$23.6** | | **Adjusted gross margin** | **71.5%** | **68.3%** | [Quantitative and Qualitative Disclosures About Market Risk](index=46&type=section&id=Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's **market risk exposures**, including interest rate and foreign currency risks, are currently **not material** - **Interest rate risk** is considered **minimal** as debt obligations carry **fixed interest rates**[252](index=252&type=chunk) - The company has exposure to **foreign currency risk** from international sales and operating expenses, but believes the **impact is not significant** at this time[253](index=253&type=chunk)[254](index=254&type=chunk) [Controls and Procedures](index=46&type=section&id=Controls%20and%20Procedures) **Material weaknesses** in **internal control over financial reporting** were identified, leading to **ineffective disclosure controls** - **Material weaknesses** were identified in **internal control over financial reporting** related to the application of **ASC 480** (Distinguishing Liabilities from Equity) and general segregation of duties, lack of **sufficient accounting resources**, and lack of a formalized risk assessment process[256](index=256&type=chunk)[257](index=257&type=chunk) - As a result of the **material weaknesses**, management concluded that the company's **disclosure controls and procedures** were **not effective** as of September 30, 2021[260](index=260&type=chunk) - The company is taking steps to remediate the **weaknesses**, including designing new review procedures, recruiting additional personnel, and developing a formal risk assessment process[258](index=258&type=chunk) [PART II—OTHER INFORMATION](index=48&type=section&id=PART%20II%E2%80%94OTHER%20INFORMATION) [Legal Proceedings](index=48&type=section&id=Item%201.%20Legal%20Proceedings) The company is not a party to any **material legal proceedings** expected to **adversely affect** its business - As of September 30, 2021, the company was not a party to any **legal proceedings** expected to have a **material adverse effect** on the business[121](index=121&type=chunk)[263](index=263&type=chunk) [Risk Factors](index=48&type=section&id=Item%201A.%20Risk%20Factors) Key risks include **potential dilution** from future equity offerings and **convertible notes**, and **integration challenges** from acquisitions - Future offerings of debt or equity securities may **dilute existing shareholders** and **adversely affect the market price** of the common stock[265](index=265&type=chunk) - The **potential conversion** of the company's **convertible notes** could result in the issuance of approximately **23.6 million** additional shares, causing **significant potential dilution**[267](index=267&type=chunk) - The company may **not realize the anticipated benefits** of acquired businesses and could face **significant difficulties integrating them**, which could **materially harm business operations**[268](index=268&type=chunk)[269](index=269&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=49&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) **Unregistered shares** were issued for **distributor acquisitions**, **earn-out consideration**, and **working capital adjustment** - On July 1, 2021, issued **479,373 shares** of **Class A Common Stock** for the **acquisitions of distributors** in France, Germany, and Mexico[272](index=272&type=chunk) - On July 15, 2021, issued **7,500,000 shares** of **Class A Common Stock** as **contingent consideration** to former **HydraFacial** stockholders[273](index=273&type=chunk)

Financial Data and Key Metrics Changes - The company reported net sales of $68.1 million, an increase of almost 100% from the previous year's COVID-impacted sales and up 72% from $39.6 million in Q3 2019 [46] - Adjusted EBITDA was $5.8 million, driven by strong net sales growth and gross margin expansion despite challenges related to the Delta variant [15][62] - Gross margin was 67.6%, up from 60.6% last year, with an adjusted gross margin of 71.5%, reflecting fixed cost leveraging and improved selling prices [53] Business Line Data and Key Metrics Changes - The Americas region saw net sales increase to $45 million, compared to $21.2 million a year ago, and over 50% growth from 2019 levels [47] - EMEA net sales grew to $12.6 million from $8.1 million in the prior year, expanding over 90% from Q3 2019 [49] - APAC net sales increased to $10.5 million, almost doubling from the prior year and over 200% from Q3 2019, driven by growth in China and Australia [50] Market Data and Key Metrics Changes - International sales were up over 105% this quarter, with significant growth in the APAC region despite COVID-related challenges [28] - The company noted strong trends in the U.S. and EMEA businesses, with continued demand for HydraFacial products [52] Company Strategy and Development Direction - The company is focused on building brand awareness, accelerating innovation, and expanding international presence as part of its strategic growth initiatives [19][34] - Plans to launch new products, including the Glow and Go at-home device, are on track, with a broader rollout expected in 2022 [38][39] - The company aims to leverage its strong financial position to pursue strategic acquisitions in a disciplined manner [31][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business model and raised the full-year 2021 guidance for net sales to $245 million to $255 million and adjusted EBITDA to approximately $30 million [32][68] - The company remains cautiously optimistic while monitoring potential risks related to COVID-19, global supply chain challenges, and inflationary pressures [70] Other Important Information - The company completed a convertible senior notes offering, raising approximately $900 million to support strategic investments [16][66] - The delivery system install base grew to over 19,000 units, reflecting strong consumer demand [71] Q&A Session All Questions and Answers Question: Insights on the connected device and revenue guidance - Management highlighted strong organic growth in consumables and the transition from analogue to digital technology with the Glow and Go device [75][76] - The company is excited about the upcoming product launches and remains on track for significant growth [77] Question: Impact of Delta variant and supply chain on guidance - Management acknowledged the Delta variant's impact on certain regions, particularly APAC, and indicated that supply chain pressures would continue to affect operations [79][101] Question: Growth drivers and international opportunities - Management emphasized the importance of international markets as a significant growth opportunity, particularly in Asia, despite ongoing challenges [88] Question: Pricing power amid inflationary pressures - The company indicated a natural increase in average selling prices due to strong demand and historical ability to pass on costs [90] Question: Delivery systems growth and channel contributions - Management noted that all channels are growing, with emerging partnerships contributing positively, while retail channels are still recovering from pandemic-related restrictions [95]

INVESTOR PRESENTATION SEPTEMBER 2021 ♡ BEAUTYHEALTH® This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company"), the calculation of certain key financial and operating metrics, capital expenditures, the introduction of new products, expansion into new markets and the ability to execute certain strategic initiatives. Some of the forward-loo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to Commission file number: 001-39565 The Beauty Health Company 2165 Spring Street (Address of principal executive offices, including zip code) Registrant ...

The Beauty Health Company (NASDAQ:SKIN) Q2 2021 Results Conference Call August 10, 2021 4:30 PM ET Company Participants Dawn Francfort - MD, ICR, Inc. Clint Carnell - CEO Liyuan Woo - CFO Conference Call Participants Matthew O’Brien - Piper Sandler Steph Wissink - Jefferies Linda Bolton Weiser - D.A. Davidson Kyle Rose - Canaccord Amit Hazan - Goldman Sachs Bruce Jackson - Benchmark Operator Good day and thank you for standing by. And welcome to The Beauty Health Company Second Quarter 2021 Earnings Call. A ...

Table of Contents For the transition period from to Commission file number: 001-39565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 The Beauty Health Company For the quarter ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in Its Charter) Indicate by check mark whether the ...

The Beauty Health Company (NASDAQ:SKIN) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Dawn Francfort – Managing Director-ICR Brent Saunders – Executive Chairman Clint Carnell – Chief Executive Officer Liyuan Woo – Chief Financial Officer Conference Call Participants Operator Greetings and welcome to The Beauty Health Company’s call to discuss the HydraFacial Company’s First Quarter Results. As a reminder, this conference is being recorded. I would now like to turn the confere ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to Commission file number: 001-39565 VESPER HEALTHCARE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 85-1908962 (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) For the quarter ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39565 Vesper Healthcare Acquisition Corp. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organization) Delaware 85-1908962 (I.R.S. Employer Identification No.) 1819 Wes ...